Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma

Cancer Treatment Reviews

Volumn 35, Issue 8, 2009, Pages 738-743

  Katodritou, Eirini ^a,c   Dimopoulos, Meletios A ^b,c   Zervas, Konstantinos ^a,c   Terpos, Evangelos ^b,c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Greek Society of Hematology   (Greece)

Author keywords

Anemia; Complications; Erythropoiesis stimulating agents; Lymphoma; Multiple myeloma; Quality of life; Survival; Thrombosis

Indexed keywords

ANTIANEMIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; MELPHALAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN RECEPTOR; VINCRISTINE;

ANEMIA; B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HUMAN; INFECTION; IRON METABOLISM; IRON OVERLOAD; LYMPHOMA; MEDICAL SOCIETY; MULTIPLE MYELOMA; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTION; QUALITY OF LIFE; RELIABILITY; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR GROWTH; UNITED STATES; UPREGULATION;

ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; IRON COMPOUNDS; LYMPHOMA; MULTIPLE MYELOMA; QUALITY OF LIFE; SURVIVAL ANALYSIS; THROMBOSIS; UP-REGULATION;

EID: 70449697965     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.08.002     Document Type: Review

References (77)

1. Kyle R.A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 50 (1975) 29-40
2. Harper P., and Littlewood T. Anemia of cancer: impact on patient fatigue and long-term outcome. Oncology 69 (2005) 2-7
3. Moullet I., Salles G., Ketterer N., et al. Frequency and significance of anaemia in non-Hodgkin's lymphoma patients. Ann Oncol 9 (1998) 1109-1115
4. Meyer R.M., Browman G.P., Samosh M.L., et al. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol 13 (1995) 2386-2393
5. Birgegard G., Gascon P., Ludwig H., et al. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. European J Haematol 77 (2006) 378-386
6. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 4 (2003) 23-29
7. Ludwig H., Rai K., Blade J., et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 3 (2002) 121-130
8. Goodnough L. Erythropoietin and iron-restricted erythropoiesis. Exp Hematol 35 (2007) 167-172
9. Weiss G., and Goodnough L. Anemia of chronic disease. N Eng J Med 352 (2005) 1011-1023
10. Sharma S., Nemeth E., Chen Y.H., et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14 (2008) 3262-3267
11. Dammacco F., Silvestris F., and Castoldi B. The effectiveness and tolerability of of epoietin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 28 (1998) 127-134
12. Osterborg A., Boogaerts M.A., Cimino R., et al. Recombinantv human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multi-center study. Blood 87 (1996) 2675-2682
13. Siedenfeld J., Piper M., Flamm C., et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93 (2001) 1204-1214
14. Bohlius J., Wilson J., Seidelfeld J., et al. Recombinant human erythropoietin in cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
15. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly non-anemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 (2005) 5960-5972
16. Henke M., Laszig R., Rube C., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
17. Wright J.R., Yng Y.C., Julian J.A., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
18. Goldberg P. Danish researchers post long-awaited Aranesp results - ever so discreetly. Cancer Lett 33 (2007) 1-6
19. Khuri F.R. Weighting the hazards of erythropoiesis stimulation in patients with cancer. N Eng J Med 356 (2007) 2445-2448
20. Rizzo J.D., Somerfield M.R., Hagerty K.L., et al. American Society of Clinical Oncology/American Society of Hematology 2007. Clinical practice guideline update on the use of epoetin and darbepoetin. J Clin Oncol 26 (2008) 132-149
21. Bohlius J., Schmidlin K., Schwarzer G., et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373 (2009) 1532-1542
22. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
23. Osterborg A., Brandberg Y., and Hedenus M. Impact of epoetin-b on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study. Br J Haematol 12 (2005) 206-209
24. Delarue R., Mounier N., Haioun C., et al. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP 21: preliminary results of the LNH03-6B Randomized GELA Study. Blood (2006) 108 [abstr 2436]
25. Hedenus M., Vansteenkiste J., Kotasek D., et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo controlled trials. J Clin Oncol 23 (2005) 6941-6948
26. Smith R.E., Aapro M.S., Ludwig H., et al. Darbepoietin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy nor radiotherapy: results of a phase III multi-center, randomized, double-blind, placebo-controlled study. J Clin Oncol 26 (2008) 1040-1050
27. Österborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematological malignancies. J Clin Oncol 20 (2002) 2486-2494
28. Food and Drug Administration Oncologic Drugs Advisory Committee. http://www.fda.gov/obrms/dockets/ac/04/briefing/4037b2.htm; 2004 [accessed 05.08].
29. Engert M., Haverkamp H., Borchmann P., et al. A prospectively randomized placeb-controlled trial of epoetin - a in patients with advanced-stage Hodgkin lymphoma: final analysis of the GHSG HD-15-EPO trial. Haematologica 94 suppl. 2 (2009) [abst 1084]
30. Shehata N., Walker I., Meyer R., et al. The use of erythropoiesis stimulating agents in patients with non-myeloid haematological malignancies: a systematic review. Ann Hematol 87 (2008) 961-973
31. San Miguel J., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Eng J Med 359 (2009) 906-917
32. Richardson P., Schlug R., Khuageva N., et al. ESAs do not adversely affect long-term outcomes nor increase the risk for thromboembolic events in multiple myeloma patients treated in the phase III VISTA trial. Blood b12 (2008) [abstr 1741]
33. Baz R., Walker E., Choueiri T.K., et al. Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. Acta Haematol 117 (2007) 162-167
34. Katodritou E., Verrou E., Hadjiaggelidou C., et al. Erythropoiesis stimulating agents are associated with reduced survival in patients with multiple myeloma. Am J Hematol 83 (2008) 697-701
35. Ludwig H., Anderson K.C., Dammaco F., et al. ESAs not the culprit: more studies required. Am J Hematol 83 (2008) 697-701
36. Katodritou E., Verrou E., and Zervas K. ESAs: not a convicted felon but still a suspect. Am J Hematol 83 (2008) 880-881
37. Steensma D. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol 83 (2008) 693-694
38. Glaspy J. Erythropoietin in cancer patients. Annu Rev Med 60 (2009) 35.1-35.12
39. Sinclair A., Todd M., Forthsythe K., et al. Expression and function of erythropoietin receptors in tumors. Cancer 110 (2007) 477-488
40. Huang J., Li C.Y., Mesa R., et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 112 (2008) 2726-2732
41. Ludwig H., Fritz E., Leitgeb C., et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84 (1994) 1056-1063
42. Cazzola M., Messinger D., Battistel V., et al. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non-Hodgkins lymphoma: dose finding and identification of predictors of response. Blood 86 (1995) 4446-4453
43. Cazzola M., Ponchio L., and Pedrotti C. Predictions of response to recombinant human erythropoietin in anemia of malignancy. Haematologica 81 (2006) 434-441
44. Littlewood T., Zagari M., Pallister C., and Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8 (2003) 99-107
45. Steinmetz T., Hellmich M., Neise M., et al. Prediction of responsiveness to treatment with erythropoiesis stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 12 (2007) 748-755
46. Katodritou E., Terpos E., Zervas K., et al. Hypochorimic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic multiple myeloma and lymphoma patients. Ann Hematol 86 (2007) 369-376
47. Katodritou E., Speletas M., Zervas K., et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 12 (2006) 47-54
48. Katodritou E., Ganz T., Terpos E., et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables and anemia response. Am J Hematol 84 (2009) 526
49. Ukarma L., Johannes H., Beyer U., et al. Hepcidin as a predictor of response to epoietin in anemic cancer patients. Clin Chem 55 (2009) 1354-1360
50. Auerbach M., Ballard H., Trout Jr., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy related anemia: a multi-center, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
51. Hedenus M., Birgegard G., Nasman P., et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative disorders. Leukemia 21 (2007) 623-627
52. Pedrazzoli P., Farris A., Del Prete S., et al. Randomized trial for intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoietin alfa. J Clin Oncol 25 (2008) 1619-1625
53. Henry D.H., Dahl N.V., Auerbach M., et al. Intravenous ferric gluconate improves response to epoietin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12 (2007) 231-242
54. Bastit L., Vandebroek A., Altintas S., et al. A randomized multi-center, controlled trial comparing the efficacy and safety of darbepoietin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 25 (2008) 1611-1618
55. Bohlius J. Is intravenous iron with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?. Nat Clin Pract Oncol 12 (2008) 688-689
56. Katodritou E., Zervas K., Terpos E., and Brugnara C. Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Haematol 142 (2008) 3-10
57. Katodritou E., Verrou E., and Zervas K. Intravenous iron: a useful therapeutic tool but not a panacea. Am J Hematol 83 (2008) 521-523
58. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci 37 (2000) 93-130
59. Bennett C.L., Silver S.M., Djulbecovic B., et al. Venous thromboembolism and mortality associated with recombinant human erythropoietin and darbepoietin administration for the treatment of cancer-related anemia. Jama 299 (2008) 914-924
60. Aapro M., Scherhag A., and Burger H.U. Effect of treatment with epoietin beta on survival, tumor progression and thromboembolic events in patients with cancer: an up-dated meta-analysis of 12 randomised controlledstidies including 2301 patients. Br J Cancer 99 (2008) 14-22
61. Agency of Healthcare Research and Quality. Comparative effectiveness of of epoietin and darbepoietin for managing anemia in patients undergoing cancer treatment. http://effectivehealthcare.ahrq.gov/>;.2006. [accessed 23.05.06].
62. Background Information of Oncologic Drugs Advisory Committee Meeting. Information package 55;. .
63. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist 13 (2008) 11-15
64. Dahl N., Henry D., and Coyne D. Thrombosis with erythropoiesis stimulating agents - does iron-deficient erythropoiesis play a role?. Sem Dial 21 (2008) 210-211
65. Khorana A.A., Francis C.W., Culakova E., et al. Risk factors for chemotherapy-associated venous thrombormbolism in a prospective observational study. Cancer 104 (2005) 2822-2829
66. Franchini M., Targher G., Montagnana M., et al. Iron and thrombosis. Ann Hematol 87 (2008) 173-176
67. Littlewood T.J., Bajetta E., Nortier J.W., et al., Epoetin alfa study group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy. Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
68. Bell D., Grimes D., Gurney H., et al. Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Intern Med J 38 (2008) 751-757
69. Dammacco F., Castoldi G., and Roedjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113 (2001) 172-179
70. Hedenus M., Adriansson M., Miguel J.S., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
71. Straus D.J., Testa M.A., Sarokhan B.J., Czuczman M.S., Tulpule A., Turner R.R., et al. Quality of life and health benefits early treatment of mild anemia. Cancer 107 (2006) 1907-1909
72. Staquet M., Berzon R., Osoba D., and Machin D. Guidelines for reporting results of quality of life assessment in clinical trials. Qual Life Res 5 (1996) 496-502
73. Borg S., Glenngård A.H., Osterborg A., et al. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model. Acta Oncol 47 (2008) 1009-1017
74. Repetto L., Moeremans K., and Annemans L. European guidelines for the management of chemotherapy induced anaemia and health economic aspects of treatment. Cancer Treat Rev 32 (2006) 5-9
75. Wilson J., Yao G.L., Raftery J., et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 13 (2007) 1-202 [iii-iv]
76. Duh M.S., Weiner J.R., White L.A., et al. Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmacoeconomics 26 (2008) 99-120
77. Norum J., and Moen M.A. Practice and costs of red blood cell (RBC) transfusion in an oncological unit. Anticancer Res 28 (2008) 459-464